Plain-English translation of NCT05914116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new experimental medication called (also called BNT324) in people with advanced cancers that have stopped responding to standard treatments. Researchers want to find the right dose of this medication and learn whether it works against certain types of cancer, either alone or combined with other hormone therapies.
Many people with advanced cancers run out of effective treatment options. This medication is designed to target a protein called B7-H3 that is found on some cancer cells, offering a potentially new way to treat cancers that have spread throughout the body.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through an IV) once every 3 weeks. The trial starts with a dose-finding phase where different groups of participants receive increasing doses to determine the safest and most effective dose. Later phases expand to specific cancer types like small cell lung cancer or prostate cancer. You would have regular visits for blood tests, imaging scans, and physical exams to monitor how you are responding and check for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States